Alessandro Riva also worked in companies including Novartis, Rhone-Poulenc Rorer and Aventis, France.
New Delhi: Drug major Glenmark Pharmaceuticals Wednesday announced the appointment of Alessandro Riva as the Chief Executive Officer (CEO) of its new innovation company based in the US. “Alessandro is currently Executive Vice President, Oncology Therapeutics and Cell Therapy for Gilead Sciences. The appointment is effective April 2, 2019,” Glenmark Pharma said in a regulatory filing.
On February 14, this year, Glenmark Pharmaceuticals had announced it has received in-principle approval from its board of directors to spin off the innovation business into a new company headquartered in the US.
“The new company will be a wholly-owned subsidiary of Glenmark and will operate with Alessandro Riva as the CEO, a management team and an independent Board of Directors,” the company added.
Alessandro also worked in companies including Novartis, Rhone-Poulenc Rorer and Aventis, France.
Commenting on the appointment, Alessandro Riva said, “I’m excited to join a company so committed to driving business through entrepreneurial innovation. The novel technology and diverse pipeline, which includes clinical-stage candidates on track to progress rapidly, has the potential to differentiate in areas of unmet need.”
“I’m looking forward to bringing my experience to lead the company and work together with highly experienced teams to deliver first-in-class therapies to the patients who need them the most,” Riva added.
The new innovation company will be headquartered in Paramus, New Jersey. Global locations include two R&D centres in Switzerland, the R&D centre at Mahape, Navi Mumbai, India, and the good manufacturing practices (GMP) biologics manufacturing facility in Switzerland, Glenmark said.
The new company will include around 400 employees working to provide an enhanced focus on the innovation business and help accelerate the pipeline towards commercialisation.
Glenmark said, its innovative products pipeline at present has eight assets, including new chemical entities (NCEs) and new biological entities (NBEs), in various stages of development in the areas of immunology, oncology and pain management.
“The pipeline includes an immuno-oncology pipeline with three bispecific antibodies developed through Glenmark’s proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) platform.
Of the five clinical and three preclinical assets in development, three clinical assets are currently in Phase 2b, and one asset is likely to enter Phase 2b in fiscal 2019-20,” the company added.